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Abstract
We report here a novel interplay between tumor suppressor p53 and nuclear receptor SHP that controls p53 and SHP
stability. Overexpression of p53 causes rapid SHP protein degradation, which does not require the presence of Mdm2 and is
mediated by the proteosome pathway. Overexpressing SHP alone does not affect p53 stability. However, SHP destabilizes
p53 by augmentation of Mdm2 ubiquitin ligase activity toward p53. The single amino acid substitution in the SHP protein
SHPK170R increases SHP binding to p53 relative to SHP wild-type, whereas SHPG171A variant shows a diminished p53
binding. As a result of the cross-regulation, the tumor suppressor function of p53 and SHP in inhibition of colon cancer
growth is compromised. Our findings reveal a unique scenario for a cross-inhibition between two tumor suppressors to
keep their expression and function in check.
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Introduction
Small heterodimer partner (SHP, NROB2) plays a critical role
in metabolic diseases [1], including bile acid biosynthesis [2,3], bile
acid and bile duct ligation (BDL) induced cholestatic liver injury
[4,5], fatty liver [6,7], hypercholesterolemia [8], glucose metab-
olism [9,10], obesity [11–13], and liver fibrosis [14]. The divergent
roles of SHP are likely contributed by its regulation of various
metabolic genes [15–18]. Our recent studies revealed another
important role of SHP in regulation of miRNA expression and
function [19–26]. In addition, growing evidence suggests SHP as a
tumor suppressor [27] in hepatocellular carcinoma (HCC) by
inhibiting hepatocyte proliferation [28], activating apoptosis [29],
and repressing the expression of DNA methyltransferase [30,31].
In spite of these important studies, the relationship between SHP
and other tumor suppressors remains largely unexplored.
p53 tumor suppressor is a transcription factor that binds to its
response elements in the Mdm2 promoter to activate Mdm2 [32].
The p53 protein stability is reduced by Mdm2 via proteasomal
degradation [33]. This creates an autoregulatory feedback loop
between p53 and Mdm2. Recent studies show that post-
translational modification of p53 and Mdm2, including phosphor-
ylation [34,35], is important for the function of p53 and Mdm2.
Phosphorylation and acetylation of p53 disrupt its interaction with
Mdm2, preventing p53 repression by Mdm2 [34,36].
Our recent study identified Mdm2 as an activator of the
ApoCIII promoter, which was repressed by p53 and SHP co-
expression [37]. We further identified a cross-talk between SHP
and Mdm2 via a feedback regulatory loop [38]. These studies
raised an interesting question whether p53 and SHP cross-regulate
each other’s stability. In the present study, we provide the first
evidence that p53 drastically decreases SHP protein stability
independent of Mdm2, and SHP in turn destabilizes p53 through
enhancing the activity of Mdm2. The findings provide new insight
into the mechanisms of cross-regulation of protein stability
between two tumor suppressors, which are important for our
better understanding the tumor suppressor function of p53 and
SHP.
Results
p53 causes rapid SHP protein degradation independent
of Mdm2
We first determined whether p53 regulates SHP protein
expression using p53 and Mdm2-double-deficient p53
2/2Mdm2
2/
2 MEFs. This will exclude the potential influence of Mdm2. Co-
expression of p53 and SHP markedly reduced SHP protein to an
undetectable level (Fig. 1A, row 3, lane 3 vs. 2), suggesting that the
downregulation of SHP by p53 does not depend on the presence
of Mdm2. Similarly, ectopic expression of Mdm2 with SHP
moderately decreased SHP (row 3, lane 4 vs. 1), suggesting that
Mdm2 was able to downregulate SHP in the absence of p53. p53
protein was drastically decreased by Mdm2 (row 2, lane 5 vs. 2).
However, SHP was degraded to the same extent in the presence of
Mdm2 regardless of the level of p53 (row 3, lane 6 vs. 3), indicating
an additive effect of Mdm2 and p53. Taken together, the results
suggest that p53 and Mdm2 independently decrease SHP protein
stability, likely by increasing its degradation.
We next determined whether p53 downregulates the endoge-
nous SHP protein using HepG2 cells, because these cells express
high basal levels of SHP [28]. As expected, overexpression of p53
reduced the levels of endogenous SHP protein in a dose-
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39789dependent fashion (Fig. 1B). In addition, the endogenous Mdm2
protein was upregulated by p53, consistent with p53’s transactiva-
tion function.
Downregulation of SHP by p53 is mediated by
proteasome degradation
Recently we discovered several naturally occurring SHP
mutations in humans [39], including SHPK170N and
SHPG171A. We mutated K170N to K170R and tested their
protein expression regulation by p53 in 293T cells. Interestingly,
p53 reduced both SHPK170R and SHPK170N proteins (Fig. 2A),
but decreased SHPK170R to a lesser extent than SHPWT.
Co-IP and Western blots revealed that SHPK170R showed
increased binding to p53 relative to SHPWT, whereas the binding
between SHPG171A and p53 was lost (Fig. 2B). The results
suggest that the binding affinity of p53 to SHP is dramatically
affected by a single amino acid substitution in the SHP protein.
We further confirmed that the SHPK170R protein was rapidly
degraded by p53 in a dose-dependent fashion (Fig. 2C). In
contrast, the amount of p53 plasmid (0.2 mg) that caused a
complete SHPK170R degradation had no effect on SHPG171A
levels and twice the amount of p53 (0.4 mg) caused only a partial
reduction of SHPG171A (Fig. 2D). Thus, the ability of p53 to
downregulate SHPG171A protein is severely impaired by the
diminished interaction between SHPG171A and p53 in 293T
cells.
The proteasome inhibitor MG132 markedly increased basal
expression of SHP but did not completely block the ability of p53
to reduce SHP protein (Fig. 2E). The histone deacetylase inhibitor
TSA, in contrast, did not affect SHP degradation by p53. In
addition, neither the levels of phosphorylated nor acetylated SHP
were altered by p53 (Fig. 2F). Furthermore, p53 increased the
levels of ubiquitinated SHP protein (Fig. 2G). Collectively, the
results suggest that p53 decreased SHP through the proteasome-
mediated pathway.
SHP does not interfere with p53 and Mdm2 interaction
To further characterize the SHP and p53 interaction, we
mapped the region of SHP required for the interaction using
various GST-SHP deletion constructs (Fig. 3A). GST pull down
assays revealed that the full length SHP (FL) and the repression
domain of SHP (Rep) showed strongest binding to p53 (Fig. 3B).
Interestingly, SHP N-terminal and its interaction domain (Int) also
bound p53 with low affinity. As expected, the lost interaction of
SHPK171A with p53 was also observed in Hela cells (Fig. 3C),
whereas other SHP mutants (R38H and K170N) did not disrupt
SHP and p53 interaction. The results are in agreement with our
observation in 293T cells (Fig. 2B–2D), which supports our
conclusion that specific amino acids rather than the entire domain
of SHP may be more important for SHP and p53 interaction that
dictates p53 functional regulation of SHP.
Due to the important relationship between p53 and Mdm2, we
determined whether SHP affected the interaction between Mdm2
and p53 using Co-IP and Western blots. Overexpressing SHP
failed to disrupt Mdm2 and p53 protein association in 293T
(Fig. 3D) and Hela cells (Fig. 3E). Therefore, the binding affinity of
SHP to p53 is weaker than the binding affinity of Mdm2 to p53.
SHP destabilizes p53 protein by enhancing the activity of
Mdm2
Thus far, we showed that p53 reduced SHP protein expression
in several cell models, including p53
2/2Mdm2
2/2 MEFs, HepG2
and 293T cells (Figs. 1, 2, 3). We also showed that the SHPG171A
and p53 interaction was lost in 293T (Fig. 2B) and Hela cells
(Fig. 3C), and that SHP did not interfere with p53 and Mdm2
interaction in both cells (Fig. 3D–3E). To determine whether SHP
regulates p53 protein expression, we overexpressed both proteins
in 293T and Hela cells. Interestingly, p53 did not modulate SHP
protein levels in Hela cells (Fig. 4A), which was confirmed by a
dose-dependent experiment (Fig. 4B). On the other hand, p53
protein was not altered by SHP co-expression in either cell types
(Fig. 4A).
Based on the above results, Hela cells were used to examine
whether SHP affected p53 protein in the presence of co-expressed
Mdm2. To our surprise, p53 protein levels were decreased by SHP
when Mdm2 was co-expressed (Fig. 4C, row 3, lane 4 vs. 2), which
correlated with the increased Mdm2 levels (row 1, lane 4 vs. 3). We
conducted in vitro ubiquitination assays to determine the effect of
SHP on Mdm2 mediated p53 ubiquitination. As expected, p53
ubiquitination was significantly increased by SHP in the presence
of Mdm2 (Fig. 4D). The effects of SHP variants on p53
ubiquitination were also compared. SHPK170R failed to increase
p53 ubiquitination mediated by Mdm2. SHPK170N, on the other
hand, further increased p53 ubiquitination compared with
SHPWT.
Because Hela cells express the HPV E6 protein, which may
interfere with physiological p53 expression, we repeated the
experiments in 293T cells. Similar to the results obtained in
Fig. 4A, co-expression of SHP and p53 decreased SHP (Fig. 4E,
row 2, lane 3 vs. 1), but not p53 protein (row 3, lane 3 vs. 2). As
expected, the level of p53 was reduced by Mdm2 (row 3, lane 5 vs.
2). A consistently decreased p53 expression was observed in the
presence of SHP and Mdm2 (row 3, lane 6 vs. 3), which likely
affected p53’s ability to downregulate SHP (row 2, lane 6 vs. 3). In
vitro ubiquitination assays showed that SHP alone did not affect
p53 uniquitination (Fig. 4F). However, Mdm2-mediated p53
uniquitination was enhanced when SHP was co-expressed
(Fig. 4G). In addition, SHPK170R diminished whereas
SHPK170N augmented p53 ubiquitination by Mdm2. SHP can
be degraded by p53 in 293T but not Hela cells, which may
Figure 1. p53 causes rapid SHP protein degradation indepen-
dent of Mdm2. A: Western blots to determine the effects of p53 and
Mdm2 on SHP protein expression in p53
2/2Mdm2
2/2 MEF cells lacking
p53 and Mdm2. The p53
2/2Mdm2
2/2 MEF cells were transfected with
Flag-SHP, Flag-p53 or Mdm2 expression vectors, and Mdm2, p53 or SHP
proteins were detected using anti-Mdm2 and anti-Flag antibodies, as
indicated. The sizes of p53 and SHP proteins are distinct, thus both
proteins were detected simultaneously using anti-Flag antibodies on
the same blot. B: Western blots to determine the effect of p53 on
endogenous SHP protein expression. Flag-p53 expression vectors were
transfected in HepG2 cells, and p53 (both endogenous and exogenous),
SHP (endogenous), and Mdm2 (endogenous) proteins were detected
using anti-p53, anti-SHP and anti-Mdm2 antibodies, respectively.
doi:10.1371/journal.pone.0039789.g001
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data demonstrate that SHP augments Mdm2-mediated p53
ubiquitination and degradation in both Hela and 293T cells.
The protein expression of p53 and Mdm2 is altered in
SHP-deficient mice
To provide physiological relevance of the cross-regulation
between SHP and p53, we determined p53 and Mdm2 proteins
Figure 2. Downregulation of SHP protein by p53 is mediated by proteosome degradation. A: Western blots to determine the effect of
p53 on SHPWT, SHPK170R, or SHPK170N protein expression. Flag-SHPWT, Flag-SHPK170R or Flag-SHPK170N expression vectors were transfected in
293T cells without or with Flag-p53 co-expression, and p53 and SHP proteins detected simultaneously using anti-Flag antibodies on the same blot. B:
Immunoprecipitation and Western blots to determine the association of SHP proteins with p53 protein. Flag-SHPWT, Flag-SHPK170R or Flag-
SHPG171A expression vectors were co-transfected with GST-p53 expression vector. Whole cell lysates were immunoprecipitated with the anti-GST
antibodies, and SHP and p53 proteins were detected using anti-Flag or anti-GST antibodies, respectively. C: Western blots to determine the effect of
p53 on SHPK170R protein levels. Flag-SHPK170R and Flag-p53 plasmids were cotransfected in 293T cells, and SHP and p53 proteins were detected
using anti-Flag antibodies. p53 and SHP protein can be easily distinguished because of different molecular weight. D: Western blots to determine the
effect of p53 on SHPG171A protein levels. Myc-p53 and Flag-SHPG171A plasmids were cotransfected in 293T cells, and p53 and SHPG171A proteins
were detected using anti-Myc and anti-Flag antibodies, respectively. E–F: Western blots to determine the effect of p53 on SHP protein expression in
the presence of MG132 or TSA (E) or on the phosphorylated and acetylated SHP protein expression (F). Flag-SHP expression vectors were transfected
alone or together with Myc-p53 vectors, and both proteins were detected using antibodies as indicated in the figures. CON, control. G: In vitro
Ubiquitination assays to determine the effect of p53 on SHP protein ubiquitination. Flag-SHP and HA-Ub expression vectors were transfected without
or with GFP-p53 vectors. Whole cell lysates were immunoprecipitated with the anti-Flag antibodies, and ubiquitinated SHP was detected using anti-
HA antibodies (indicated by a solid line).
doi:10.1371/journal.pone.0039789.g002
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2/2 mice. Consistent with our prior
observation that SHP enhances Mdm2 protein stability [38], the
hepatic Mdm2 protein expression was markedly decreased by
SHP-deficiency (Fig. 5). As expected, the levels of p53 protein were
increased in SHP
2/2 livers compared with the wild-type mice.
The results provide strong in vivo evidence for SHP induction of
Mdm2 protein and reduction of p53 protein expression.
SHP and p53 inhibition of HCT116 tumor growth is
compromised
Like p53, our recent studies showed that SHP also functions as a
tumor suppressor [27–29]. Because p53 and SHP destabilize each
other, we examined the tumor suppressive effects of SHP and p53
on HCT116 tumor growth. Overexpression of either SHP or p53
decreased the number of colonies formed by HCT116p53
+/+ cells
(Fig. 6A, upper panel). The individual effect of SHP and p53 was
not further enhanced by co-expression of either protein. Foci
formation assays showed that individual expression of SHP or p53
decreased foci numbers and that co-expression of both proteins
reversed their individual effect in the HCT116p53
2/2 cells
(Fig. 6A, lower panel). The p53
+/+ and p53
2/2 cells exhibited a
similar ability to grow tumors in nude mice (Fig. 6B, tumor 2 vs. 1).
Expression of SHP or p53 inhibited tumor growth in both p53
+/+
and p53
2/2 cells. The tumor weight tended to be higher in p53
2/
2 cells co-expressing SHP and p53 than in cells expressing SHP
alone. However, due to the variation of individual tumor volume,
the difference did not reach significance. SHP degradation by p53
seems to be more dramatic when p53 is re-expressed in p53-
deficient cells (p53
2/2 MEFs, Fig. 1A) than in cells that contain
p53 (Fig. 2B, Fig. 3E), which may contribute to the differential
outcome between p53
+/+ and p53
2/2 cells. In addition, overex-
pression of p53 markedly inhibited foci formation in SHP-deficient
MEF cells (Fig. 6C).
Discussion
In the present study, we provide convincing evidence for a
cross-talk between p53 and nuclear receptor SHP. We show that
p53 is able to downregulate SHP in MEFs, HepG2 and 293T cells,
but not in Hela cells. On the contrary, SHP regulates p53 protein
in a similar fashion in both 293T and Hela cells. SHP alone does
not alter p53 protein expression, nor interfere with p53 and Mdm2
interaction, but it augments p53 degradation by Mdm2 through
ubiquitination.
One prior report revealed a crosstalk among nuclear receptor
TR3 (Nur77), p53, and Mdm2 [40]. Interestingly, TR3 binding to
p53 blocks p53 ubiquitination mediated by Mdm2, while SHP
downregulates p53 protein by increasing its degradation through
Mdm2. Therefore, SHP and TR3 play distinct roles in regulating
the p53-Mdm2 pathway.
We recently elucidated an autoregulatory feedback loop
between Mdm2 and SHP proteins [38]. In the study, we showed
that the endogenous SHP protein was co-immunoprecipitated
with the endogenous Mdm2 and p53 protein in HepG2 cells using
specific anti-SHP, anti-Mdm2 and anti-p53 antibodies. In the
present study, we showed that the K170 and G171 residues in the
SHP protein are important for SHP and p53 interaction to
regulate p53-mediated SHP stability as well as SHP-mediated p53
stability via Mdm2. In addition, the Mdm2 protein was reduced
whereas the p53 protein was induced in SHP
2/2 livers compared
with the wild-type mice. Therefore, the SHP and p53 interaction
has a clear physiological relevance.
As a consequence of the cross-inhibition between SHP and p53,
an antagonizing effect between SHP and p53 was observed in
HCT116p53
+/+ and p53
2/2 cells. The SHP and p53 in inhibiting
tumor formation in both cells appear to be different, which is likely
affected by the endogenous p53 function.
Figure 3. SHP does not interfere p53 and Mdm2 interaction. A–B: GST pull down to determine the in vitro interaction of SHP with p53. Flag-
p53 was in vitro translated and used to interact with various GST-SHP fusion proteins, including GST-FL (full length), GST-2 (interaction domain), GST-
1+2 (repression domain deletion), GST-3 (repression domain), and GST-2+3 (N-terminal domain deletion), that were expressed from bacterial
Escherichia coli BL21/DE3/RIL. C: Immunoprecipitation and Western blots. Plasmids expressing Myc-p53 were cotransfected with Flag-SHPWT, Flag-
SHP38H, Flag-SHP170N, and Flag-SHP171A plasmids in Hela cells. Co-IP and WB were performed with corresponding antibodies as indicated. D–E:
Western blots to determine the effect of SHP on p53 and Mdm2 interaction. D: HA-Mdm2 (2 mg), Myc-p53 (4 mg) and Flag-SHP (2 mg) plasmids were
cotransfected in 293T cells, and their proteins were detected using anti-HA, anti-Myc and anti-Flag antibodies, respectively. E: HA-Mdm2 (2 mg), Flag-
p53 (4 mg) and Flag-SHP (2 mg) plasmids were cotransfected in Hela cells, and their proteins were detected using anti-HA and anti-Flag antibodies,
respectively.
doi:10.1371/journal.pone.0039789.g003
p53 and SHP Crosstalk
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39789Our finding of decreased stability of SHP upon p53 overex-
pression is somewhat different from a recent report that stability of
the SHP protein was increased in HepG2 cells treated with the
p53 activator doxorubicin (DXR) [41]. However, the direct effect
of p53 overexpression or knockdown on SHP stability was not
tested. The discrepancy between the studies could be due to the
different experimental conditions that were used.
Based on findings from our recently published study on SHP
and Mdm2 crosstalk [38], and the present study on SHP and p53
crosstalk, we propose a fine tuned interplay among SHP, Mdm2
and p53 (Fig. 7). SHP interacts physically with Mdm2 through
Figure 4. SHP destabilizes p53 protein by enhancing the activity of Mdm2. A: Western blots. Plasmids expressing Flag-p53 were co-
transfected with Flag-SHP plasmids in 293T or Hela cells. p53 or SHP protein levels were determined using anti-Flag antibodies. B: Western blots. Flag-
SHP and Myc-p53 plasmids were cotransfected in Hela cells, and SHP and p53 proteins were detected using anti-Flag and anti-Myc antibodies,
respectively. C: Western blots. Myc-p53, Flag-SHP or HA-Mdm2 expression vectors were transfected in Hela cells, and Mdm2, SHP and p53 proteins
were detected using anti-HA, anti-Flag or anti-Myc antibodies, respectively. D: Ubiquitination assays. Hela cells were cotransfected with GFP-p53, HA-
Mdm2, and various Flag-SHP expression vectors together with Myc-ubiquitin (Myc-Ub) plasmids. GFP-p53 was immunoprecipitated from cell extracts
with anti-GFP antibodies, and ubiquitinated p53 in the immunoprecipitates was detected by Western blots with anti-Myc antibodies. Positions of
ubiquitinated p53 proteins are indicated by a solid line. E: Western blots. HA-Mdm2, Flag-p53 or Flag-SHP expression vectors were transfected in 293T
cells, and Mdm2, SHP and p53 proteins were detected using anti-HA or anti-Flag antibodies, respectively. F: Ubiquitination assays. 293T cells were
cotransfected with Flag-p53 and GFP-SHP expression vectors together with HA-ubiquitin (HA-Ub) plasmids. Flag-p53 was immunoprecipitated from
cell extracts with anti-Flag antibodies, and ubiquitinated p53 in the immunoprecipitates was detected by Western blots with anti-HA antibodies.
Positions of ubiquitinated p53 proteins are indicated by a solid line. G: Ubiquitination assays. 293T cells were cotransfected with GFP-p53, HA-Mdm2,
and various Flag-SHP expression vectors together with Myc-ubiquitin (Myc-Ub) plasmids. GFP-p53 was immunoprecipitated from cell extracts with
anti-GFP antibodies, and ubiquitinated p53 in the immunoprecipitates was detected by Western blots with anti-Myc antibodies. Positions of
ubiquitinated p53 proteins are indicated by a solid line.
doi:10.1371/journal.pone.0039789.g004
p53 and SHP Crosstalk
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increase in Mdm2 destabilizes p53, contributing to SHP augmen-
tation of Mdm2-mediated p53 ubiquitination and degradation. In
turn, p53 downregulates SHP by targeting the protein for
proteasomal degradation, through an undefined mechanism.
Mdm2 also moderately decreases SHP, and its effect is strongly
augmented by p53-deficiency, thus creating an autoregulatory loop
with SHP. It should be noted that the interaction between p53 and
Mdm2 is much stronger than the interaction of SHP with p53 or
Mdm2. Presumably then the reciprocal regulation of p53 and
Mdm2 predominates over the interaction with SHP when all three
Figure 5. Mdm2 protein is upregulated and p53 protein is
downregulated in SHP
2/2 mice. Western blots to determine
endogenous p53 and Mdm2 proteins in the livers of wild-type and
SHP
2/2 mice. Five mice per genotype were analyzed.
doi:10.1371/journal.pone.0039789.g005
Figure 6. SHP and p53 inhibition of HCT116 tumor growth was compromised. A: Colony formation assays (upper panel) and foci formation
assays (lower panel). Left: HCT116p53
+/+ and HCT116p53
2/2 cells were transduced with GFP, SHP or p53 adenoviruses (Ad) as indicated, and colony
(upper) or foci (lower) formation was analyzed. The experiment was repeated 4 times (duplicate or triplicate/time) and one representative result is
shown. Right: statistical analysis of the results on the left. Data are represented as mean 6 SEM. *p,0.01 vs. white bar;
¥p,0.01 vs. black or grey bar.
B: Tumorigenesis assays. HCT116p53
+/+ and HCT116p53
2/2 cells were transduced with GFP, SHP or p53 adenoviruses (Ad) and were either injected
into the same or different mouse (left and right flanks). Each experimental group was injected into three flanks (one flank/mouse, three mice). Tumors
were collected 2 weeks later. Left: representative tumor images from each group. Right: statistical analysis of tumor volume (n=3/group). *p,0.01 vs.
GFP group corresponding to p53
+/+ or p53
2/2 cells. C: Foci formation assays in SHP
2/2 MEF cells that were overexpressed with GFP control or p53
adenoviruses. Three representative images per group are shown.
doi:10.1371/journal.pone.0039789.g006
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mechanisms controlling p53 and Mdm2 stability mediated by a
nuclear receptor.
Overall our results suggest that depending on the cellular
context and relative levels of the three proteins, SHP, p53, and
Mdm2 may act in concert to determine susceptibility to
carcinogenesis.
Materials and Methods
Plasmids, cell lines and reagents
Plasmids and cells were obtained from Drs. Takeshi Imamura
(HA-Ub) [42], Yang Shi (Myc-Ub) [43], Paul Neilsen (Myc-p53)
[44], Guillermina Lozano (p53
2/2Mdm2
2/2 MEFs) [45], and
David Jones (HCT116p53
+/+, and HCT116p53
2/2 cells). Other
plasmids or cell lines were from our laboratory [39] or purchased
from Addgene. Antibodies against human MDM2, HA-tag, and b-
actin were purchased from Sigma. p53 antibody was obtained
from Santa Cruz. M2 antibody, anti-Flag M2 Magnetic Beads and
anti-HA agarose were purchased from Sigma. Mouse monoclonal
antibody against Myc-tag was purchased from Cell Signaling.
MG132 was purchased from Cayman.
Cell culture and transfection
p53
2/2Mdm2
2/2 MEFs, HepG2, HEK293T, Hela,
HCT116p53
+/+, and HCT116p53
2/2 cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal
bovine serum. Transfection was performed by Lipofectamine 2000
according to the manufacturer’s instructions. Colony formation
assay [22,28] was performed as described in our previous
publications.
Co-immunoprecipitation and Western blots
HEK293T cells were transfected with the indicated plasmids
using Lipofectamine 2000 (Invitrogen), lysed in 500 ml lysis buffer
and immunoprecipitated with anti-Flag M2 Magnetic Beads
(Sigma) or anti-GFP antibodies for 4 hr at 4uC. The beads were
washed four times with the lysis buffer. The bound proteins were
separated by SDS-PAGE, followed by Western blotting with the
indicated antibodies according to the standard procedures.
Ubiquitination assay
Flag-SHP, GFP-p53, HA-Mdm2, or GFP-SHP, Flag-p53, HA-
Mdm2, as indicated in each figure, were transfected with HA-ubi
or myc-ubi into HEK293T cells for 24 hr, then treated with
5 mM MG132 (Cayman) for additional 6 hr. Cells were harvested
and lysed in 500 ul of lysis buffer and immunoprecipitated with
anti-Flag M2 magnetic beads (Sigma) or anti-GFP antibodies for
4h ra t4 uC. The beads were washed three times with the lysis
buffer and analyzed with anti-GFP, anti-Flag, anti-HA, or anti-
myc antibodies by Western blots, as indicated in the figures.
Foci Formation
HCT116 cells (1610
6) were infected with adenoviruses as
indicated in the figure legends for 2 hr (multiplicity of infection,
100). Cells grew for 1 day and 2.5610
4 cells were suspended with
1.5 ml of 0.4% top agar and 26McCoy’s 5a medium before being
poured onto 6 well tissue culture plate coated with 1.5 ml of 0.7%
bottom agar. The plates were prepared in triplicate. Ten days
later, 6 areas per plate were chosen randomly and the number of
visible colonies was counted and used for statistical analysis.
Mouse Xenograft Model
Six-week-old female athymic nude mice nu/nu were used for
HCT116 tumor xenografts. Both flanks of each mouse were
injected with 1610
6 cells mixed with Matrigel Matrix HC (BD
biosciences) in a total volume of 200 ml. After 2 weeks, tumors
were dissected out and weighed. Protocols for animal use were
approved by the Institutional Animal Care and use Committee at
the University of Utah (IACUC number: 10-06010, approved 06-
13-2011).
Statistical analysis
Data are expressed as mean 6 SEM. Statistical analyses were
carried out using Student’s unpaired t test; p , 0.01 was
considered statistically significant.
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